Table 5.
West Cumbria12 | Caithness14 | West Berkshire16 | Ontario45 | Record linkage study22
|
Present study
|
||||
---|---|---|---|---|---|---|---|---|---|
All data | Without west Cumbria | All data | Without Cumbria | ||||||
Study description | |||||||||
Design | Case-control | Case-control | Case-control | Case-control | Case-control | Cohort | |||
Age range(years) | 0–24 | 0–24 | 0–4 | 0–14 | 0–14 | 0–24 | |||
Years of diagnosis | 1950–85 | 1970–86 | 1972–89 | 1950–88 | 1952–1986 | 1 1951–1993 | |||
All malignancies | |||||||||
Monitored | No data | No data | No data | No data | 1.3 (0.9 to 1.9) | 1.3 (0.9 to 1.9) | 1.4 (0.9 to 2.2) | 1.5 (0.9 to 2.5) | |
⩾ 100 mSv | No data | No data | No data | No data | 1.2 (0.3 to 4.3) | 0.7 (0.1 to 3.4) | 2.2 (0.9 to 5.3) | 4.1 (1.4 to 11.8) | |
Leukaemia and non-Hodgkin’s lymphoma | |||||||||
Monitored | 1.1 (0.5 to 2.7) | Not reported | 9.0 (1.0 to 108.8) | No data | 1.8 (1.1 to 3.0) | 1.8 (1.1 to 3.0) | 1.8 (0.7 to 4.4) | 2.2 (0.7 to 6.6) | |
⩾100 mSv | 8.6 (1.4 to 52.2) | 0.0 | No data | No data | 1.4 (0.3 to 7.2) | 0.5 (0.0 to 5.2) | 3.9 (1.0 to 15.7) | 4.3 (0.5 to 40.5) | |
Leukaemia | |||||||||
Monitored | 1.4 (0.5 to 3.9) | Not reported | Not reported | 1.0 (0.5 to 2.2) | Not reported | Not reported | 2.2 (0.8 to 6.1) | 2.9 (0.8 to 10.3) | |
⩾ 100 mSv | 8.4 (1.4 to 52.0) | Not reported | No data | 0.0 | Not reported | Not reported | 5.8 (1.3 to 24.8) | 6.6 (0.7 to 67.1) | |
All malignancies except leukaemia and non-Hodgkin’s lymphoma | |||||||||
Monitored | No data | No data | No data | No data | 0.9 (0.6 to 1.6) | 1.3 (0.7 to 2.2) | 1.3 (0.7 to 2.3) | ||
⩾ 100 mSv | No data | No data | No data | No data | 1.0 (0.1 to 13.8) | 1.5 (0.5 to 5.0) | 4.0 (1.2 to 13.6) |
Further details of these studies are shown in table 6. Results from Kinlen et al’s study20 are not shown since their data were included in the record-linkage study.22 23 Findings from the case-control study conducted near the La Hague plant are also not shown since no estimates of risk were reported for monitored workers and there were no reports of workers with doses of 100 mSv or more.46